Health In Tech, Inc. Q4 2025 Earnings Call Summary

Performance was driven by a distribution-led model that expanded the partner network by 34% to 858 brokers and TPAs, though management notes penetration remains below 0.1% of the total U.S. broker market.
The company successfully transitioned up-market by extending its EDIBS platform to support employers with over 100 employees, moving beyond its initial small-group focus.
Operational efficiency is anchored by compressing underwriting timelines for large employers from approximately three months to roughly two weeks through automated workflows.
Management attributes its competitive moat to a proprietary HIPAA-governed dataset and integrated marketplace workflow rather than standalone AI models.
Strategic positioning focuses on solving industry fragmentation by connecting underwriting, plan design, and stop-loss administration in a single, execution-ready platform.
The three-year rate stabilization program was introduced to address pricing volatility, specifically targeting the predictability needs of municipalities and government entities.

Full year 2026 revenue guidance of $45,000,000 to $50,000,000 assumes 35% to 50% growth, supported by high visibility into recurring revenue from 12-month policy cycles.
The company plans to evolve into a fully integrated marketplace by extending capabilities into claims administration and cost-containment solutions.
Guidance assumes a rapid ‘time to revenue’ framework where new platform features are expected to scale within one to two quarters of launch.
Strategic focus for 2026 includes a beta test for a data-driven solution integrating physiological and claims data to provide actionable health insights.
Management expects the largest volume of new business for the rate stabilization program to align with the January 1 renewal cycle, particularly for public sector clients.

The company reported a fourth-quarter net loss of $300,000, attributed to planned reinvestments in go-to-market initiatives and peak enrollment activity costs.
Seasonality in employer renewal cycles can cause quarterly variance; management advises evaluating performance on a year-over-year basis rather than sequentially.
Operating leverage improved as total operating expenses fell to 58% of revenue in 2025, a 16% year-over-year improvement driven by G&A efficiencies.
The company maintains a disciplined approach to pharmacy benefit management (PBM) integration, citing regulatory uncertainty as a reason for a cautious ‘wait and see’ stance.